531 related articles for article (PubMed ID: 29615063)
21. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
22. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
25. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Cerbelli B; Pernazza A; Botticelli A; Fortunato L; Monti M; Sciattella P; Campagna D; Mazzuca F; Mauri M; Naso G; Marchetti P; d'Amati G; Costarelli L
Biomed Res Int; 2017; 2017():1750925. PubMed ID: 29387716
[TBL] [Abstract][Full Text] [Related]
27. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
29. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
30. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
[TBL] [Abstract][Full Text] [Related]
31. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
32. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
34. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
37. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
38. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract][Full Text] [Related]
40. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.
Asano Y; Kashiwagi S; Onoda N; Kurata K; Morisaki T; Noda S; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Br J Cancer; 2016 Jan; 114(1):14-20. PubMed ID: 26757422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
